Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation

European Urology

Volumn 67, Issue 6, 2015, Pages 1195-1196

  Ali, Siraj M ^a   Miller, Vincent A ^a   Ross, Jeffrey S ^a   Pal, Sumanta K ^b  

^a FOUNDATION MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EVEROLIMUS; GEMCITABINE; MEMBRANE PROTEIN; NF2 PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CYSTECTOMY; FEMALE; GENE MUTATION; HUMAN; LETTER; LYMPH NODE DISSECTION; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; PELVIC PAIN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; BLADDER; CARCINOMA, TRANSITIONAL CELL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; MUTATION; NEUROFIBROMATOSIS TYPE 2; PATHOLOGY; UROLOGIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA, TRANSITIONAL CELL; EVEROLIMUS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEUROFIBROMATOSIS 2; TAXOIDS; TREATMENT OUTCOME; URINARY BLADDER; UROLOGIC NEOPLASMS;

EID: 84929999263     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.01.015     Document Type: Letter

References (5)

1. G.M. Frampton, A. Fichtenholtz, and G.A. Otto Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Nat Biotechnol 31 2013 1023 1031
2. NCT01215136. First-line everolimus +/- paclitaxel for cisplatin-ineligible patients with advanced urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01215136
3. G. Sonpavde, C.N. Sternberg, J.E. Rosenberg, N.M. Hahn, M.D. Galsky, and N.J. Vogelzang Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium Lancet Oncol 11 2010 861 870
4. G. Iyer, A.J. Hanrahan, and M.I. Milowsky Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
5. N. Wagle, B.C. Grabiner, and E.M. Van Allen Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov 4 2014 546 553